Floatz logo

nm32-2668

Peritoneal Carcinoma

Numab Therapeutics AGPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Peritoneal Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
CanariaBio Inc.
Phase 3BB
Eloxatin
University of Utah
Phase 2B
STAPULDENCEL
SOTIO a.s.
Phase 3B
Interferon Gamma-1B
InterMune
Phase 3B
Gefetinib
Massachusetts General Hospital
Phase 2B

View all 18 →

Same molecule, other indications

nm32-2668 is also rated in:

lung adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
liposarcomaDormant
CC
Indicative ·
43 / 100
View asset →
gastric adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →